Anand S, Montez-Rath M, Han J, et al. - Researchers aimed at determining the seroprevalence of SARS-CoV-2 spike protein receptor binding antibodies in a nationwide representative sample of patients receiving dialysis. The remainder plasma of 28,503 patients receiving dialysis throughout the USA were assessed using a chemiluminescence assay with high sensitivity and specificity. Findings yielded evidence of seroconversion in, overall, fewer than 10% of US adults in July, 2020, despite of the fact that the USA is contemporaneously leading the world in the numbers of diagnosed cases. Evidence of exposure or immune response was not gained in a vast majority of US adults, including people receiving dialysis who are among the highest risk for mortality upon contracting SARS-CoV-2. In addition, the likelihood of SARS-CoV-2 seropositivity was higher for residents of predominantly Black and Hispanic neighbourhoods (two to three times higher), poorer areas (two times higher), and the most densely populated areas (ten times higher). Early decrease in community mobility in March, 2020, was linked with 60% lower chances of individual-level seroconversion by July that year.